Aspire Biopharma (NASDAQ:ASBP) Shares Down 4% – Should You Sell?

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBPGet Free Report)’s stock price was down 4% during trading on Monday . The company traded as low as $0.31 and last traded at $0.32. Approximately 1,689,340 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 40,553,096 shares. The stock had previously closed at $0.33.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen lowered Aspire Biopharma to a “strong sell” rating in a research report on Saturday, July 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Get Our Latest Stock Report on ASBP

Aspire Biopharma Trading Down 4.0%

The firm has a 50 day moving average price of $0.43.

Aspire Biopharma (NASDAQ:ASBPGet Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.04) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ASBP. Jane Street Group LLC lifted its holdings in shares of Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares in the last quarter. Optivise Advisory Services LLC increased its holdings in shares of Aspire Biopharma by 120.9% in the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after buying an additional 128,660 shares during the last quarter. Crewe Advisors LLC raised its stake in shares of Aspire Biopharma by 100.0% in the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after acquiring an additional 313,427 shares during the period. Finally, Procyon Advisors LLC raised its stake in shares of Aspire Biopharma by 558.3% in the second quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock valued at $174,000 after acquiring an additional 549,911 shares during the period. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Aspire Biopharma Company Profile

(Get Free Report)

Aspire Biopharma Holdings, Inc, early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management.

Recommended Stories

Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.